Home › NDC Lookup › RxCUI directory › RxCUI 311913

Naproxen 25 MG/ML Oral Suspension — RxCUI 311913

RxNorm drug concept · Semantic clinical drug
RxCUI 311913 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI311913
Official nameNaproxen 25 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnaproxen 125 MG per 5 ML Oral Suspension; naproxen 125 MG in 5 mL Oral Suspension
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)15,803 prescriptions · 36 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Naproxen: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • They're very similar — naproxen sodium is just the salt form of naproxen, and it dissolves in water more quickly. That means your body absorbs naproxen sodium a bit faster, so it t...
  • What's the difference between naproxen and naproxen sodium — are they the same thing?
  • You can take it either way, but taking it with food, milk, or a full glass of water is a good idea because it helps protect your stomach. Naproxen can irritate the lining of your s...
  • Can I take naproxen on an empty stomach, or do I need to eat first?
📖 Read our full Naproxen guide →

🕸️ Concept Web — How Naproxen 25 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Naproxen 25 MG/ML Oral Suspension RxCUI 311913

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Naproxen 7258
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Naprosyn 203012
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Naproxen Oral Suspension 373004
    • Naproxen Oral Liquid Product 1157516
    • Naproxen Oral Product 1157517
    • Naproxen Oral Suspension [Naprosyn] 93416
    • Naprosyn Oral Liquid Product 1179303
    • Naprosyn Oral Product 1179304
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Naproxen 25 MG/ML 317653
    • Naproxen 25 MG/ML Oral Suspension [Naprosyn] 207093
    • Naproxen 25 MG/ML [Naprosyn] 567887

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Naproxen 25 MG/ML SCDC · 317653
  • Naproxen Oral Suspension SCDF · 373004
  • Naproxen Oral Liquid Product SCDG · 1157516
  • Naproxen Oral Product SCDG · 1157517

Brand-Name Concepts

  • Naproxen 25 MG/ML Oral Suspension [Naprosyn] SBD · 207093
  • Naproxen 25 MG/ML [Naprosyn] SBDC · 567887
  • Naproxen Oral Suspension [Naprosyn] SBDF · 93416
  • Naprosyn Oral Liquid Product SBDG · 1179303
  • Naprosyn Oral Product SBDG · 1179304
  • Naprosyn BN · 203012

📦 FDA Products & Package NDCs

6 products · 6 package NDCs
6 package NDCs map to RxCUI 311913 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00054-3630-63 500 mL in 1 BOTTLE, PLASTIC (0054-3630-63) Naproxen Hikma Pharmaceuticals USA Inc. 2021-02-24
31722-0682-05 500 mL in 1 BOTTLE (31722-682-05) Naproxen Camber Pharmaceuticals, Inc. 2022-06-07
42192-0619-16 473 mL in 1 BOTTLE (42192-619-16) Naproxen Acella Pharmaceuticals, LLC 2020-11-12
59651-0528-47 1 BOTTLE in 1 CARTON (59651-528-47) / 473 mL in 1 BOTTLE Naproxen Aurobindo Pharma Limited 2025-10-03
69238-1730-02 473 mL in 1 BOTTLE (69238-1730-2) Naproxen Amneal Pharmaceuticals NY LLC 2020-08-03
70954-0151-10 500 mL in 1 BOTTLE (70954-151-10) Naproxen Oral Suspension ANI Pharmaceuticals, Inc. 2021-03-12
Observed labelers: Acella Pharmaceuticals, LLC (1) · Amneal Pharmaceuticals NY LLC (1) · ANI Pharmaceuticals, Inc. (1) · Aurobindo Pharma Limited (1) · Camber Pharmaceuticals, Inc. (1) · Hikma Pharmaceuticals USA Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.